- Conditions
- Left Ventricular Diastolic Dysfunction
- Interventions
- BNP (nesiritide), Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2569–2592
of 7,076
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Oral Food Refusal
- Interventions
- Amitriptyline, Placebo, Megestrol
- Drug
- Lead sponsor
- Ann Davis, PhD, MPH, ABPP
- Other
- Eligibility
- 9 Months to 8 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Kansas City, Kansas • New Orleans, Louisiana • Columbus, Ohio
- Conditions
- Racial Disparities, Blood Pressure, Cardiovascular Risk Factor, Renal Function
- Interventions
- MitoQ
- Dietary Supplement
- Lead sponsor
- Auburn University
- Other
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Auburn, Alabama
- Conditions
- Rheumatoid Arthritis
- Interventions
- PTC844, Placebo
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 14
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Phoenix, Arizona + 10 more
- Conditions
- Hypereosinophilic Syndrome
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 8
- States / cities
- La Jolla, California • Atlanta, Georgia • Bethesda, Maryland + 5 more
- Conditions
- Down Syndrome
- Interventions
- Rivastigmine, Liquid Placebo
- Drug · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Durham, North Carolina
- Conditions
- Healthy
- Interventions
- alprazolam, Placebo, PF-00572778
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4
- Interventions
- Sulforaphane (Avmacol Extra Strength), Placebo
- Drug · Dietary Supplement
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Lixisenatide (AVE0010), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 10 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Chula Vista, California • Overland Park, Kansas • Louisville, Kentucky
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency
- Interventions
- Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule, Cohort 2 CTAP101 Capsules - 30µg, Cohort 2 Matching Sugar Capsule
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bannockburn, Illinois
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 15
- States / cities
- Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more
- Conditions
- Lumbar Spinal Stenosis, Thoracic Spinal Stenosis
- Interventions
- Tranexamic Acid, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Asthma
- Interventions
- Reslizumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arkansas + 62 more
- Conditions
- Differentiated Thyroid Cancer (DTC)
- Interventions
- Dabrafenib, Trametinib, Trametinib Placebo, Dabrafenib placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Lung Injury, Acute
- Interventions
- SB-681323 Intravenous 3mg, SB-681323 Intravenous 7.5 mg, SB-681323 Intravenous 7.5mg, SB-681323 Intravenous 10mg, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- Lexington, Kentucky • Durham, North Carolina • Winston-Salem, North Carolina + 3 more
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Molnupiravir, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 32
- States / cities
- Peoria, Arizona • Los Angeles, California • North Hollywood, California + 27 more
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Interventions
- VGX-3100, Placebo, Electroporation (EP)
- Biological · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 22
- States / cities
- Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
- Conditions
- Urticaria
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 40
- States / cities
- Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more
- Conditions
- Covid19
- Interventions
- Bardoxolone Methyl, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 8
- States / cities
- Springfield, Illinois • Brooklyn, New York • Elmhurst, New York + 2 more
- Conditions
- Tuberous Sclerosis Complex, Epilepsy
- Interventions
- Sirolimus, Placebo
- Drug
- Lead sponsor
- Darcy Krueger
- Other
- Eligibility
- 1 Day to 6 Months
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 5 more
- Conditions
- COVID-19
- Interventions
- Placebo, Remdesivir, Baricitinib
- Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1,033 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more
- Conditions
- Asthma
- Interventions
- Oglemilast, Placebo then Oglemilast
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alopecia Areata
- Interventions
- JNJ-64304500, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Plainfield, Indiana • Louisville, Kentucky + 5 more
- Conditions
- Muscle Spasticity
- Interventions
- XP19986 SR1, 10 mg BID, XP19986 SR1, 20 mg BID, XP19986 SR1, 30 mg BID, Placebo
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 11
- States / cities
- Downey, California • Gilroy, California • Pasadena, California + 8 more